Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Feb 29;13(2):353-355.
doi: 10.21037/tau-23-588. Epub 2024 Feb 1.

The final report of KEYNOTE-426 showed the efficacy and safety as a treatment for advanced renal cell carcinoma

Kojiro Ohba  1 , Ryoichi Imamura  1
Affiliations
Editorial

The final report of KEYNOTE-426 showed the efficacy and safety as a treatment for advanced renal cell carcinoma

Kojiro Ohba et al. Transl Androl Urol. .
No abstract available

Keywords: Axitinib; immune checkpoint inhibitor (ICI); pembrolizumab; tyrosine-kinase inhibitor (TKI).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-23-588/coif). The authors have no conflicts of interest to declare.

Comment on

References

    1. Motzer RJ, McDermott DF, Escudier B, et al. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer 2022;128:2085-97. 10.1002/cncr.34180 - DOI - PMC - PubMed
    1. Powles T, Plimack ER, Soulières D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol 2020;21:1563-73. Erratum in: Lancet Oncol 2020;21:e553. 10.1016/S1470-2045(20)30436-8 - DOI - PubMed
    1. Haanen JBAG, Larkin J, Choueiri TK, et al. Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma. ESMO Open 2023;8:101210. 10.1016/j.esmoop.2023.101210 - DOI - PMC - PubMed
    1. Motzer RJ, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol 2022;23:888-98. Erratum in: Lancet Oncol 2022;23:e319. Erratum in: Lancet Oncol 2022;23:e404. 10.1016/S1470-2045(22)00290-X - DOI - PMC - PubMed
    1. Choueiri TK, Eto M, Motzer R, et al. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. Lancet Oncol 2023;24:228-38. Erratum in: Lancet Oncol 2023;24:e146. 10.1016/S1470-2045(23)00049-9 - DOI - PubMed